Investors in Capricor Therapeutics, Inc. face a Sept. 28, 2026, deadline to seek lead plaintiff status in a federal securities class action covering purchases or acquisitions from Dec. 17, 2025, through July 26, 2026. Faruqi & Faruqi, LLP is investigating allegations that Capricor and certain executives misled investors about deramiocel, an investigational cell therapy for Duchenne muscular dystrophy, including changes to the trial’s pre-specified statistical analysis plan without prior FDA agreement before resubmitting the Biologics License Application. The FDA said in briefing documents released July 27 that deramiocel’s benefit-risk assessment appeared unfavorable without evidence of effectiveness, sending Capricor shares down $12.70, or 64%, to $7.00. After an FDA Advisory Committee voted 9-3 on July 29 that available evidence did not support deramiocel’s efficacy for DMD-associated cardiomyopathy, shares fell another $2.38, or 36%, to $4.19 on July 30. The FDA separately extended the application’s target action date from Aug. 22 to Nov. 22, 2026, after receiving additional Phase 3 HOPE-3 data and a proposed narrower indication focused on upper-limb function. Investors do not need to serve as lead plaintiff to participate in any potential recovery.